204 related articles for article (PubMed ID: 25665670)
1. CUP Syndrome in Neuroendocrine Neoplasia: Analysis of Risk Factors and Impact of Surgical Intervention.
Begum N; Wellner U; Thorns C; Brabant G; Hoffmann M; Bürk CG; Lehnert H; Keck T
World J Surg; 2015 Jun; 39(6):1443-51. PubMed ID: 25665670
[TBL] [Abstract][Full Text] [Related]
2. [Diagnostics and therapy for neuroendocrine neoplasia of an unknown primary - a plea for open exploration].
Begum N; Hubold C; Buchmann I; Thorns C; Bouchard R; Lubienski A; Schlöricke E; Zimmermann M; Lehnert H; Bruch HP; Bürk CG
Zentralbl Chir; 2014 Jun; 139(3):284-91. PubMed ID: 23508839
[TBL] [Abstract][Full Text] [Related]
3. Role of Ki-67 proliferation index in the assessment of patients with neuroendocrine neoplasias regarding the stage of disease.
Miller HC; Drymousis P; Flora R; Goldin R; Spalding D; Frilling A
World J Surg; 2014 Jun; 38(6):1353-61. PubMed ID: 24493070
[TBL] [Abstract][Full Text] [Related]
4. [Clinicopathological characteristics and prognosis analysis of colorectal neuroendocrine neoplasms based on the data from domestic six medical centers].
Zhang Y; Peng X; Jin K; Wang W; Feng X; Zeng Y; Chen M; Yu X; Chen Y; Chen J
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1235-1240. PubMed ID: 27928792
[TBL] [Abstract][Full Text] [Related]
5. Neuroendocrine neoplasms of liver - A 5-year retrospective clinico-pathological study applying World Health Organization 2010 classification.
Burad DK; Kodiatte TA; Rajeeb SM; Goel A; Eapen CE; Ramakrishna B
World J Gastroenterol; 2016 Oct; 22(40):8956-8966. PubMed ID: 27833387
[TBL] [Abstract][Full Text] [Related]
6. [Subtype classification and clinicopathological characteristics of gastric neuroendocrine neoplasms: an analysis of 241 cases].
Zhang P; Zhang Y; Zhang C; Shi Y; Liu J; Liu Q; Yu L; Wang M; Zou G; Lou J; Chen J; Tan H
Zhonghua Wei Chang Wai Ke Za Zhi; 2016 Nov; 19(11):1241-1246. PubMed ID: 27928793
[TBL] [Abstract][Full Text] [Related]
7. [Prognostic analysis of colon and rectal neuroendocrine neoplasm in different stages].
Huang YT; Jia R; Xu Q; Ji SJ; Cui HT; Xu JM
Zhonghua Zhong Liu Za Zhi; 2019 Feb; 41(2):146-151. PubMed ID: 30862146
[No Abstract] [Full Text] [Related]
8. Predictors of long-term outcome in patients with well-differentiated gastroenteropancreatic neuroendocrine tumors after peptide receptor radionuclide therapy with 177Lu-octreotate.
Ezziddin S; Attassi M; Yong-Hing CJ; Ahmadzadehfar H; Willinek W; Grünwald F; Guhlke S; Biersack HJ; Sabet A
J Nucl Med; 2014 Feb; 55(2):183-90. PubMed ID: 24434296
[TBL] [Abstract][Full Text] [Related]
9. Analysis of risk factors for recurrence after curative resection of well-differentiated pancreatic neuroendocrine tumors based on the new grading classification.
Tsutsumi K; Ohtsuka T; Fujino M; Nakashima H; Aishima S; Ueda J; Takahata S; Nakamura M; Oda Y; Tanaka M
J Hepatobiliary Pancreat Sci; 2014 Jun; 21(6):418-25. PubMed ID: 24142395
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of the concordance between the stage of the disease and Ki-67 proliferation index in gastroenteropancreatic neuroendocrine tumors.
Özaslan E; Demir S; Karaca H; Güven K
Eur J Gastroenterol Hepatol; 2016 Jul; 28(7):836-41. PubMed ID: 26945127
[TBL] [Abstract][Full Text] [Related]
11. Neuroendocrine tumors (NETs) of unknown primary: is early surgical exploration and aggressive debulking justifiable?
Wang YZ; Chauhan A; Rau J; Diebold AE; Opoku-Boateng A; Ramcharan T; Boudreaux JP; Woltering EA
Chin Clin Oncol; 2016 Feb; 5(1):4. PubMed ID: 26932428
[TBL] [Abstract][Full Text] [Related]
12. Multicenter Analysis of Presacral Neuroendocrine Neoplasms-Clinicopathological Characterization and Treatment Outcomes of a Rare Disease.
Matrood S; Apostolidis L; Schrader J; Krug S; Lahner H; Ramaswamy A; Librizzi D; Kender Z; Kröcher A; Kreutzfeldt S; Gress TM; Rinke A
Front Endocrinol (Lausanne); 2021; 12():709256. PubMed ID: 34690926
[TBL] [Abstract][Full Text] [Related]
13. MIB-1 Index-Stratified Assessment of Dual-Tracer PET/CT with
Sampathirao N; Basu S
J Nucl Med Technol; 2017 Mar; 45(1):34-41. PubMed ID: 28154019
[TBL] [Abstract][Full Text] [Related]
14. The influence of comorbidities, age, and performance status on the prognosis and treatment of patients with metastatic carcinomas of unknown primary site: a population-based study.
Seve P; Sawyer M; Hanson J; Broussolle C; Dumontet C; Mackey JR
Cancer; 2006 May; 106(9):2058-66. PubMed ID: 16583433
[TBL] [Abstract][Full Text] [Related]
15. Pancreatic neuroendocrine tumors: A single-center 20-year experience with 100 patients.
Shiba S; Morizane C; Hiraoka N; Sasaki M; Koga F; Sakamoto Y; Kondo S; Ueno H; Ikeda M; Yamada T; Shimada K; Kosuge T; Okusaka T
Pancreatology; 2016; 16(1):99-105. PubMed ID: 26718527
[TBL] [Abstract][Full Text] [Related]
16. Extra-appendiceal neuroendocrine neoplasms in children - data from the GPOH-MET 97 Study.
Redlich A; Wechsung K; Boxberger N; Leuschner I; Vorwerk P
Klin Padiatr; 2013 Nov; 225(6):315-9. PubMed ID: 24158887
[TBL] [Abstract][Full Text] [Related]
17. Low serum albumin levels and liver metastasis are powerful prognostic markers for survival in patients with carcinomas of unknown primary site.
Seve P; Ray-Coquard I; Trillet-Lenoir V; Sawyer M; Hanson J; Broussolle C; Negrier S; Dumontet C; Mackey JR
Cancer; 2006 Dec; 107(11):2698-705. PubMed ID: 17063500
[TBL] [Abstract][Full Text] [Related]
18. Hepatic metastases from carcinomas of unknown primary site.
Pouessel D; Thezenas S; Culine S; Becht C; Senesse P; Ychou M
Gastroenterol Clin Biol; 2005 Dec; 29(12):1224-32. PubMed ID: 16518276
[TBL] [Abstract][Full Text] [Related]
19. Bone metastasis and poor performance status are prognostic factors for survival of carcinoma of unknown primary site in patients treated with systematic chemotherapy.
Kodaira M; Takahashi S; Yamada S; Ueda K; Mishima Y; Takeuchi K; Yamamoto N; Ishikawa Y; Yokoyama M; Saotome T; Terui Y; Hatake K
Ann Oncol; 2010 Jun; 21(6):1163-1167. PubMed ID: 20019088
[TBL] [Abstract][Full Text] [Related]
20. Grading of neuroendocrine neoplasms: mitoses and Ki-67 are both essential.
van Velthuysen ML; Groen EJ; van der Noort V; van de Pol A; Tesselaar ME; Korse CM
Neuroendocrinology; 2014; 100(2-3):221-7. PubMed ID: 25358267
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
